DraftUnitedHealthcarePolicy CS334ID.A

Prostate Surgeries and Interventions (for Idaho Only)

Clinical coverage guidance for prostate procedures and interventions (Idaho only), including indications deemed proven/medically necessary and those considered unproven or not medically necessary. Affects providers delivering prostate-related surgical and minimally invasive procedures for UnitedHealthcare members in Idaho, including Idaho Medicaid Plus.

Policy Summary

PayerUnitedHealthcare

PolicyProstate Surgeries and Interventions (for Idaho Only)

Policy CodePolicy CS334ID.A

Change TypeNo material change

Effective DateJun 1, 2025

Next Review DateN/A

Key ActionObtain prior authorization per plan rules and provide clinical documentation showing eligibility (IPSS, prostate volume, Qmax, prior therapies) when requesting coverage for minimally invasive prostate procedures.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Idahojurisdiction

multipleprocedures discussed

InterQual referencedInterQual cited

181Aquablation RCT N

21%

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

PAE retreatment rate

Coverage Criteria and Evidence Summaries

inv-01: Transurethral ablation — covered when InterQual criteria met

For medical necessity clinical coverage criteria, InterQual is the reference for specific inclusion/exclusion details.

Medical necessity statement: Transurethral ablation of the prostate is proven and medically necessary in certain circumstances.

Refer to InterQual CP: Procedures, Prostatectomy, Transurethral Ablation for the specific clinical inclusion and exclusion criteria.

inv-02: Cryoablation — recurrent prostate cancer

Covered when used for recurrent prostate cancer diagnosed by biopsy; evidence for other indications is limited.

Covered indication: Cryoablation is proven and medically necessary for recurrent prostate cancer diagnosed by biopsy.

Refer to InterQual CP: Procedures, Cryoablation, Prostate for clinical necessity determination.

Evidence summary: Systematic reviews report heterogeneous observational evidence (including large case series) and limited randomized data; oncologic outcomes in recurrent disease support use but primary-treatment evidence is inconsistent and additional high-quality research is needed.

See systematic reviews cited in policy.

inv-03: PUL (UroLift) — FDA labeled indications and contraindications

Covered when performed within the FDA labeled indications and absent listed contraindications.

Covered when ALL of the following are met: PUL (prostatic urethral lift, UroLift) is proven and medically necessary when used to treat LUTS due to BPH in men ≥45 years in accordance with FDA labeled indications, and none of the following contraindications are present: prostate volume > 100 cc; active urinary tract infection; urethral conditions precluding insertion of the delivery system; urinary incontinence due to an incompetent sphincter; or current gross hematuria.prostate volume <= 100 cc

Follow device Instructions for Use and FDA labeled indications; PUL is unproven/not medically necessary for other indications.

inv-04: Water vapor thermotherapy — covered per InterQual

Refer to InterQual for exact clinical eligibility.

Medical necessity statement: High-energy water vapor thermotherapy (Rezūm) for BPH is proven and medically necessary in certain circumstances.

Refer to InterQual CP: Procedures, Prostatectomy, Transurethral Ablation for specific clinical criteria; use for malignant prostate tissue is unproven/not medically necessary.

inv-05: Water jet ablation — for LUTS due to BPH

Proven for treatment of LUTS due to BPH when performed as tissue resection/removal.

Covered indication: Transurethral water jet ablation (Aquabeam/Aquablation) is proven and medically necessary for resection/removal of prostate tissue to treat lower urinary tract symptoms due to benign prostatic hyperplasia.

Unproven and not medically necessary for indications beyond treatment of LUTS due to BPH.

inv-06: Biodegradable spacer placement — with radiotherapy

Covered when used with radiotherapy for prostate cancer and appropriate procedural documentation is available.

Covered indication: Transperineal placement of biodegradable peri‑prostatic material (e.g., hydrogel spacer) is proven and medically necessary when placed as an adjunct to prostate radiotherapy to reduce rectal dose and toxicity.

Trials commonly required treatment planning imaging (CT/MRI) and fiducial placement; some pivotal trials excluded prostate volume >80 mL—document applicability if outside trial populations.

inv-07: PAE and other procedures — covered for specific indications; several procedures unproven

PAE is selectively covered; several listed procedures are unproven for routine use.

PAE covered indications: Prostate artery embolization (PAE) is proven and medically necessary for patients who are ineligible for other procedures due to surgical constraints (for example, very large prostate size) or anesthesia risk, or for persistent gross hematuria originating from the prostate.

PAE is unproven/not medically necessary for other indications and should be reserved for selected patients; prior conservative therapy and justification should be documented.

Unproven procedures: The following are considered unproven and not medically necessary for routine use due to insufficient evidence: transperineal focal laser ablation (FLA), insertion of a temporary prostatic urethral stent, transperineal laser ablation (TPLA) for general use, ablation of malignant prostate tissue by magnetic field induction, and transurethral drug‑coated balloon dilation.

Refer to individual procedure sections for detailed evidence summaries and exclusions.

inv-08: Cryoablation (primary and salvage) evidence

Evidence is heterogeneous; interpret oncologic outcomes with caution.

Cryoablation evidence points: Systematic reviews identify heterogeneous observational studies (including large case series) and limited randomized data; for recurrent disease oncologic outcomes and survival are reported but secondary outcomes and harms are inconsistently reported.

Additional high-quality research is needed to clarify comparative effectiveness and safety.

Cryoablation limitations: Lack of randomized trials for focal cryo and substantial heterogeneity across studies limit broad generalizability.

May affect coverage determinations outside proven recurrent‑disease indication.

inv-09: Prostatic Urethral Lift (PUL)

RCT and randomized comparisons support durable symptom benefit and a favorable recovery/sexual function profile.

PUL trial evidence: Randomized, blinded sham‑controlled and randomized comparative trials demonstrate durable symptom improvement, faster early recovery, and relative preservation of sexual function compared with TURP; TURP may provide greater improvement in flow metrics but PUL preserves ejaculatory function and accelerates recovery.

Trials commonly included IPSS and Qmax eligibility criteria and prostate volume limits (see device labeling and trials).

inv-10: Aquablation (Waterjet) evidence

Randomized and observational evidence supports symptom and flow improvements; device preserves ejaculatory function in many patients.

Aquablation randomized evidence: A multicenter, double‑blind RCT (WATER I) met noninferiority versus TURP for symptom relief at 6 months and multi‑year follow‑up (2–5 years) shows durable IPSS and Qmax improvements with low retreatment rates.

RCT inclusion typically limited to prostate sizes up to ~80 mL; other series include larger glands (up to 150 mL).

Aquablation supportive evidence: Meta‑analyses and multiple single‑arm series report substantial IPSS improvement (~16 points at 1 year), improved uroflow, and favorable safety profiles though evidence quality varies and many studies are manufacturer‑sponsored.

Longer‑term comparative data against other minimally invasive options remain limited.

inv-11: High-energy water vapor thermotherapy

No peer‑reviewed original data identified for malignant‑tissue use in this search.

Water vapor therapy evidence: A literature search did not identify peer‑reviewed original data supporting high‑energy water vapor thermotherapy for ablation of malignant prostate tissue.

No evidence in this excerpt to support clinical conclusions for malignant‑tissue indications.

inv-12: Hydrogel spacer (SpaceOAR/DuraSeal) — covered with criteria

Randomized and cohort trial data show reduced rectal dose and lower rectal toxicity when used with prostate radiotherapy.

Hydrogel spacer candidate criteria: Transperineal hydrogel (PEG) rectal spacers (e.g., SpaceOAR) are proven and medically necessary when placed to reduce rectal radiation dose and late rectal toxicity in men undergoing prostate radiotherapy; candidate selection in trials included localized prostate cancer (T1–T2) with treatment planning by CT/MRI and fiducial placement.

Pivotal trials excluded prostate volume >80 mL and prior pelvic radiation or surgery in some studies; document applicability if outside trial populations.

inv-13: Aquablation — informational / investigational

Early single‑arm data exist but are limited by small sample size and lack of controls.

Aquablation evidence: Single‑arm prospective studies (n=21 and other small cohorts) report symptom and objective flow improvements up to 12 months, but evidence is limited by small sample sizes and lack of concurrent controls.

Considered informational; larger RCT data summarized separately.

inv-14: PAE — investigational/conditional coverage

Evidence supports short‑term symptom improvement but randomized trials show inferior functional outcomes and higher retreatment rates versus TURP.

PAE comparative outcomes: Systematic reviews and randomized trials report that PAE can improve patient‑reported LUTS and short‑term QoL with fewer immediate complications and shorter hospitalization versus TURP, but TURP provides superior long‑term functional outcomes and PAE has higher retreatment rates (e.g., 21% requiring TURP within 2 years in a randomized trial).

Certainty of evidence ranges low to moderate; consider PAE investigational or limited to selected high‑risk or refractory patients unless further evidence supports broader use.

inv-15: PAE — comparative outcomes and recommended cautious use

PAE outcomes show mixed strength of evidence and require careful patient selection.

PAE evidence and selection: PAE demonstrates safety and symptom improvement in multiple studies but shows inferior improvements in many functional measures versus TURP in randomized trials and a clinically significant re‑treatment rate; evidence limitations (small trials, short follow‑up, heterogeneity) warrant cautious use and documentation of prior conservative therapy and reasons for surgical ineligibility.

PAE may be appropriate for patients who are poor surgical candidates or refractory to medical therapy; require documentation of prior therapies and informed consent regarding comparative outcomes.

inv-16: FLA/TPLA — insufficient evidence for routine use

Focal therapies have limited oncologic evidence; routine use outside clinical trials is not recommended.

FLA evidence: Focal laser ablation and other focal therapies have limited, low‑certainty evidence for oncologic effectiveness; although functional outcomes may be favorable, oncologic effectiveness versus standard treatments is not established and routine use should be confined to clinical trials or prospective comparative studies.

Suitability depends on tumor grade, MRI visibility, biopsy confirmation, and careful patient selection per consensus statements.

inv-17: TPLA — promising but inconclusive

Pilot studies and a small RCT suggest benefit but evidence remains inconclusive.

TPLA evidence: Transperineal laser ablation (TPLA) pilot studies and a small randomized study show symptom improvement and preserved sexual function compared with TURP in short‑term follow‑up, but sample sizes are small and longer‑term comparative effectiveness is inconclusive.

Recommend larger multicenter randomized trials before broad adoption.

inv-18: Temporary stents (iTind) — limited evidence; consider experimental or conditional use

Limited randomized and prospective evidence with mixed results; consider conditional use in select patients.

iTind evidence: Temporary implanted nitinol device (iTind) trials demonstrate some IPSS improvement versus sham and durability to 12 months in many patients, but results are mixed, primary endpoints not consistently met, and risk of bias and follow‑up loss limit conclusions.prostate volume 25-75 cc; IPSS >= 10; Qmax <= 12 mL/sec

Consider use in patients matching trial inclusion criteria or within clinical studies; document eligibility metrics and counsel patients on limited long‑term evidence and variable outcomes.

inv-19: Guideline‑based patient selection for minimally invasive BPH devices

Coverage should align with guideline‑based patient selection for each device or minimally invasive procedure.

AUA/EAU selection criteria: Patient meets guideline‑specified clinical criteria for the specific minimally invasive BPH device or procedure (examples include prostate volume within device‑specified range, absence of obstructive median/middle lobe when required, and symptom severity per IPSS) and the procedure is offered consistent with guideline recommendation strength.see thresholds

Examples: PUL per AUA—prostate 30–80 g and absence of obstructive middle lobe (moderate rec). Robotic waterjet and water vapor therapy generally considered for prostate volumes ~30–80 g in guideline statements; temporary implanted devices: prostate volume 25–75 g and lack of obstructive median lobe (expert opinion).

inv-20: Ablation of malignant prostate tissue by magnetic field induction

Insufficient evidence to support routine clinical use outside trials.

Insufficient evidence: Ablation of malignant prostate tissue by magnetic nanoparticle induction is investigational due to inconsistent intratumoral nanoparticle distribution, technical challenges, and reports of significant adverse events; further robust randomized trials and long‑term outcomes are required before clinical implementation.N/A

Phase I data reported grade 3 urinary toxicities and declines in several quality‑of‑life domains.

inv-21: Transurethral drug-coated balloon (Optilume)

Trial evidence shows short‑term benefit but longer‑term comparative data are limited.

Clinical trial evidence summary: Transurethral drug‑coated balloon (Optilume) demonstrated improvements in IPSS and Qmax through one year in randomized sham‑controlled data (PINNACLE), but longer‑term comparative effectiveness and safety data are limited.N/A

Consider coverage conditional on meeting trial‑like selection criteria (e.g., IPSS, Qmax, prostate volume) and availability of longer‑term evidence; document exclusions such as prior prostate procedures, PSA >10 without negative biopsy, active UTI, and PVR >300 mL as per trial.

The policy identifies multiple procedures as unproven and not medically necessary when used outside the specific indications described elsewhere in this document. Examples explicitly listed include cryoablation for primary treatment, ablation of malignant prostate tissue by magnetic field induction, transperineal focal laser ablation, insertion of temporary prostatic urethral stents, transperineal laser ablation (TPLA), and transurethral drug‑coated balloon dilation. These procedures may be considered not medically necessary for all other indications due to insufficient evidence of safety and/or efficacy.

Evidence for focal cryotherapy is heterogeneous and limited: systematic reviews and narrative summaries identify mostly observational studies, variable outcome reporting, and few or no randomized controlled trials specific to focal cryo. The lack of RCT data and inconsistency in oncologic and functional outcome reporting constrains generalizability and supports restricting focal cryotherapy use to research settings or clearly defined indications supported by higher‑quality data.

Several pivotal trials and registries excluded patients with larger prostates or enrolled small cohorts, limiting applicability to broader populations. For example, the pivotal SpaceOAR hydrogel spacer trial excluded prostate volumes > 80 mL. Early Aquablation evidence includes a single‑arm prospective study with only 21 patients and lacks concurrent controls; these sample size and exclusion criteria limit confidence in extrapolating results to patients outside trial entry criteria.

Routine use of focal therapies, including focal laser ablation (FLA/TPLA), for primary treatment of clinically localized prostate cancer is not recommended outside of clinical trials. Systematic reviews conclude the evidence is low certainty, with mixed oncologic outcomes and methodological limitations; therefore, adoption for routine care should be deferred until robust randomized data demonstrate oncologic equivalence and acceptable long‑term outcomes.

Magnetic nanoparticle thermal ablation for malignant prostate tissue is unsupported by current evidence and should be limited to clinical trials. Early phase studies report technical challenges with intratumoral nanoparticle distribution, inconsistent thermal dosing, and occurrence of grade 3 urinary toxicities and meaningful declines in patient‑reported social and role functioning, indicating insufficient data to support routine clinical use.

This Medical Policy is provided for informational purposes and does not supersede federal, state, or contractual benefit plan coverage terms. In the event of a conflict, the applicable federal, state, or contractual requirements govern; providers should verify plan‑specific coverage and prior authorization requirements before proceeding.

Procedures listed as unproven or not medically necessary in this policy should be considered non‑covered for indications beyond the specific, supported uses described. For example, cryoablation is considered proven only for biopsy‑proven recurrent prostate cancer and is not medically necessary for initial prostate cancer treatment; high‑energy water vapor thermotherapy and other novel ablative or stent/balloon procedures are unproven for malignant prostate tissue and other off‑label indications.

A targeted literature search did not identify peer‑reviewed original data supporting the use of high‑energy water vapor thermotherapy in malignant prostate tissue; therefore, evidence is insufficient to draw clinical conclusions and the therapy is considered investigational for malignancy.

Prostate artery embolization (PAE) may be considered not medically necessary when proposed as first‑line surgical therapy in patients who are otherwise suitable candidates for standard surgical options (for example TURP). Randomized and systematic review evidence shows PAE provides short‑term symptom improvement and favorable perioperative safety, but TURP achieves superior long‑term functional outcomes and lower retreatment rates.

PAE should not be considered equivalent to established surgical therapies for all patients. Randomized trials and meta‑analyses report smaller improvements in IPSS and objective functional measures after PAE compared with TURP, and higher retreatment rates (for example, approximately 21% of PAE patients required TURP within 2 years in a randomized trial), so PAE's role should be limited to selected patients (e.g., poor surgical candidates) or research settings.

Temporary urethral/prostatic stents and some temporary implanted prostatic devices (TIPD, e.g., iTind) have limited and mixed evidence. Trials include small randomized and single‑arm studies with variable follow‑up and risk of bias; while some patients derive symptomatic benefit, inconsistent trial results, loss to follow‑up, and safety signals mean these devices should be used cautiously and preferably within trial settings or when patients meet strict selection criteria documented in the medical record.

Applicable CPT/HCPCS code listings are provided for reference in the coding tables of this policy. Inclusion of a code in the policy does not imply the service is covered under a given plan; benefit coverage is determined by federal, state, or contractual requirements and applicable laws.

Applicable CPT / HCPCS Codes (group 2)CPT

0582T	Transurethral ablation of malignant prostate tissue by high-energy water vapor thermotherapy, including intraoperative imaging and needle guidance.
0619T	Cystourethroscopy with transurethral anterior prostate commissurotomy and drug delivery, including transrectal ultrasound and fluoroscopy, when performed.
0655T	Transperineal focal laser ablation of malignant prostate tissue, including transrectal imaging guidance, with MR-fused images or other enhanced ultrasound.
0714T	Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance; prostate volume less than 50mL.
0738T	Treatment planning for magnetic field induction ablation of malignant prostate tissue, using data from previously performed magnetic resonance imaging (MRI) examination.
0739T	Ablation of malignant prostate tissue by magnetic field induction, including all intraprocedural, transperineal needle/catheter placement for nanoparticle installation and intraprocedural temperature monitoring, thermal dosimetry, bladder irrigation, and magnetic field nanoparticle activation.
0867T	Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance; prostate volume greater or equal to 50mL.
37243	Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural road mapping, and imaging guidance necessary to complete the intervention: for tumors, organ ischemia, or infarction (when performed on prostate tissue).
52441	Cystourethroscopy, with insertion of permanent adjustable transprostatic implant; single implant.
52442	Cystourethroscopy, with insertion of permanent adjustable transprostatic implant; each additional permanent adjustable transprostatic implant (List separately in addition to code for primary procedure).

Applicable CPT / HCPCS Codes (group 3)CPT

53850	Transurethral destruction of prostate tissue; by microwave thermotherapy.
53852	Transurethral destruction of prostate tissue; by radiofrequency thermotherapy.
53854	Transurethral destruction of prostate tissue; by radiofrequency generated water vapor thermotherapy.
53855	Insertion of a temporary prostatic urethral stent, including urethral measurement.
55873	Cryosurgical ablation of the prostate (includes ultrasonic guidance and monitoring).
55874	Transperineal placement of biodegradable material, peri-prostatic, single or multiple injection(s), including image guidance, when performed.

No explicit codes in this excerptmixed

No codes listed

Codes referenced in documentmixed

No codes listed

PAE and comparator procedures (study level)mixed

none listed

Document text reports study interventions (PAE, TURP) but provides no billing codes in this section

TPLA / FLA (study level)mixed

none listed

TPLA / focal laser studies referenced; no procedural codes provided in text

Temporary urethral stents (iTind)mixed

none listed

iTind temporary urethral stent device discussed; no specific billing codes provided

Device regulatory references mentionedmixed

K193269	UroLift 510(k) reference (device clearance)
K191505	Rezum 510(k) reference (device clearance)
DEN190020 / K210138	iTind De Novo (DEN190020) and subsequent 510(k) K210138 references
Product code OVB	Rectal spacer devices 510(k) product code reference
Product code FAD	Ureteral stents 510(k) product code reference
DEN160040	Embosphere Microspheres De Novo for prostatic artery embolization
K202961	Aquabeam 510(k) reference

Device regulatory references (no billing codes provided in these chunks)mixed

No codes listed

Prior Authorization, Documentation, and Operational Guidance

Prior Authorization

Prior authorization per InterQual for key procedures

Prior authorization is required in accordance with InterQual clinical coverage criteria for specific procedures (for example, transurethral ablation, cryoablation, high‑energy water vapor thermotherapy). Submit documentation that demonstrates clinical eligibility per the referenced InterQual pathways.

Prior authorization required when applicable per plan and InterQual criteria.
Follow payer-specific submission process and timelines.

Documentation Required

Prior authorization: clinical eligibility documentation

Document clinical eligibility fully when requesting prior authorization. Include age, baseline International Prostate Symptom Score (IPSS), Qmax (maximum urinary flow rate), prostate volume (cc/mL), presence or absence of median (middle) lobe, prior treatments and response, and current medications (alpha‑blocker, 5‑alpha‑reductase inhibitor).

Include relevant imaging or TRUS measurements when applicable.

Applicable Billing and Regulatory Codes

Applicable CPT / HCPCS Codes (group 1)CPT

0421T

Transurethral waterjet ablation of prostate, including control of post-operative bleeding, including ultrasound guidance, complete (vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, and internal urethrotomy are included when performed)

Applicable CPT / HCPCS Codes (group 2)CPT

0582T	Transurethral ablation of malignant prostate tissue by high-energy water vapor thermotherapy, including intraoperative imaging and needle guidance.
0619T	Cystourethroscopy with transurethral anterior prostate commissurotomy and drug delivery, including transrectal ultrasound and fluoroscopy, when performed.
0655T	Transperineal focal laser ablation of malignant prostate tissue, including transrectal imaging guidance, with MR-fused images or other enhanced ultrasound.
0714T	Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance; prostate volume less than 50mL.
0738T	Treatment planning for magnetic field induction ablation of malignant prostate tissue, using data from previously performed magnetic resonance imaging (MRI) examination.
0739T	Ablation of malignant prostate tissue by magnetic field induction, including all intraprocedural, transperineal needle/catheter placement for nanoparticle installation and intraprocedural temperature monitoring, thermal dosimetry, bladder irrigation, and magnetic field nanoparticle activation.
0867T	Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance; prostate volume greater or equal to 50mL.
37243	Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural road mapping, and imaging guidance necessary to complete the intervention: for tumors, organ ischemia, or infarction (when performed on prostate tissue).
52441	Cystourethroscopy, with insertion of permanent adjustable transprostatic implant; single implant.
52442	Cystourethroscopy, with insertion of permanent adjustable transprostatic implant; each additional permanent adjustable transprostatic implant (List separately in addition to code for primary procedure).

Applicable CPT / HCPCS Codes (group 3)CPT

53850	Transurethral destruction of prostate tissue; by microwave thermotherapy.
53852	Transurethral destruction of prostate tissue; by radiofrequency thermotherapy.
53854	Transurethral destruction of prostate tissue; by radiofrequency generated water vapor thermotherapy.
53855	Insertion of a temporary prostatic urethral stent, including urethral measurement.
55873	Cryosurgical ablation of the prostate (includes ultrasonic guidance and monitoring).
55874	Transperineal placement of biodegradable material, peri-prostatic, single or multiple injection(s), including image guidance, when performed.

No explicit codes in this excerptmixed

No codes listed

Codes referenced in document (aggregate)mixed

No codes listed

PAE and comparator procedures (study level)mixed

none listed

Document text reports study interventions (PAE, TURP) but provides no billing codes in this section

TPLA / FLA (study level)mixed

none listed

TPLA / focal laser studies referenced; no procedural codes provided in text

Temporary urethral stents (iTind)mixed

none listed

iTind temporary urethral stent device discussed; no specific billing codes provided

Device regulatory references mentionedmixed

K193269	UroLift 510(k) reference (device clearance)
K191505	Rezum 510(k) reference (device clearance)
DEN190020 / K210138	iTind De Novo (DEN190020) and subsequent 510(k) K210138 references
Product code OVB	Rectal spacer devices 510(k) product code reference
Product code FAD	Ureteral stents 510(k) product code reference
DEN160040	Embosphere Microspheres De Novo for prostatic artery embolization
K202961	Aquabeam 510(k) reference

Device regulatory references (no billing codes provided in these chunks)mixed

No codes listed

Prostate volume limit for PUL (UroLift)

PUL prostate volume limitProstate volume must be ≤ 100 cc (contraindication: prostate volume >100 cc)

Age requirement (FDA labeled)Men 45 years of age or older

Contraindications listedActive urinary tract infection, urethral conditions preventing delivery system insertion, urinary incontinence due to incompetent sphincter, current gross hematuria

Prostate volume inclusion ranges reported in studies

Common study inclusion ranges — small to moderate glands

Background and Definitions

Benign prostatic hyperplasia (BPH) is a common condition in men older than 50 that can cause lower urinary tract symptoms (LUTS) due to urethral compression from prostate enlargement. Initial management typically includes lifestyle measures and medical therapy; minimally invasive procedures and surgical options are considered for patients who fail medical management or have complications. Multiple device‑based and ablative technologies exist with varying levels of evidence for symptom relief, functional outcomes, and safety.

Definition — High-energy water vapor thermotherapy (Rezūm)

DefinitionHigh-energy water vapor thermotherapy (Rezūm) uses thermal water vapor to reduce prostate volume associated with BPH, including central zone and middle lobe hyperplasia.

Intended effectReduces prostate tissue volume to relieve lower urinary tract symptoms while minimizing risks associated with more invasive surgery.

Example systemRezūm System described in device and clinical literature

Definition — Transurethral water jet ablation (Aquabeam)

Policy Revision History

2025-06-01New Medical PolicyLatest

Policy established as a new medical policy (New Medical Policy).

When implementing revisions or interpreting this policy, remember that plan‑specific benefit documents, federal and state mandates, and contractual requirements take precedence over this Medical Policy. Providers should verify member benefit terms and prior authorization rules before delivering services; UnitedHealthcare may use third‑party tools such as InterQual to assist in benefit administration, but those tools do not override contractual coverage provisions.

Policy Summary

PayerUnitedHealthcare

PolicyProstate Surgeries and Interventions (for Idaho Only)

Policy CodePolicy CS334ID.A

Change TypeNo material change

Effective DateJun 1, 2025

Next Review DateN/A

SourceLink

On This Page

For PAE requests, include prior medical therapy trial details and reasons for surgical ineligibility if claiming high surgical risk.

Prior Authorization

PAE prior authorization suggested

Prostate artery embolization (PAE) — prior authorization is suggested given the current evidence base and variable long‑term outcomes compared with TURP. Payers may require additional documentation or limit coverage to investigational pathways or trial settings.

Highlight if patient is high surgical risk or unsuitable for TURP.
Provide informed consent documentation showing discussion of higher retreatment rates (reported ~21% requiring TURP within 2 years).

Prior Authorization

PAE — prior authorization recommended for investigational use

PAE is considered investigational in some settings due to inconsistent functional outcomes and retreatment rates; prior authorization is recommended when PAE is requested outside guideline‑preferred indications. Provide robust clinical rationale and long‑term follow‑up plan.

If requesting coverage as investigational, include rationale, supporting literature, and plan for monitoring and follow up.
Be prepared for peer review or requests for additional evidence.

Documentation Required

Guideline‑based selection required

Select procedures using guideline‑based recommendations (AUA, EAU). When there are guideline‑preferred alternatives (e.g., TURP, HoLEP, PUL under specific anatomic criteria), document why the chosen intervention is appropriate for the patient.

If requesting a guideline‑recommended procedure, include how patient meets guideline criteria (prostate size, median lobe status, symptom severity).
If deviating from guideline preference, include justification and prior conservative therapy tried.

Note

Prior authorization guidance — follow payer plan documents for code‑specific requirements

Follow the payer plan documents and benefit contract for code‑specific prior authorization rules. This policy provides clinical guidance but does not replace contractual or state/federal coverage requirements.

When plan documents and this policy conflict, follow federal/state/contractual requirements.
Use InterQual tools as specified by UnitedHealthcare for clinical adjudication.

Denial Risk

Evidence‑quality risk — limited/heterogeneous data may prompt denials

Evidence for some procedures (for example, cryoablation, PAE, temporary stents, certain novel devices) is limited or heterogeneous. This uncertainty may increase the likelihood of peer‑to‑peer review requests or claim denials.

Small single‑arm studies, heterogeneous populations, and short follow‑up durations contribute to evidence‑quality risk.
Be prepared to supply long‑term outcomes and RCT data where available.

Denial Risk

Evidence limitations may trigger denial

Evidence limitations (small sample sizes, single‑arm studies, short follow‑up, loss to follow‑up) may be used as a basis for coverage denial or classification as investigational. Provide the strongest available evidence and detailed patient‑level data when requesting coverage.

For devices or procedures with limited evidence, include RCT data if available, patient selection criteria consistent with trials, and planned monitoring.
Document alternative treatments tried and reasons for failure or ineligibility.

Note

Plan vs Policy conflict — follow federal/state/contractual terms when differing

When this policy differs from a member's federal, state, or contractual benefit plan, the federal/state/contractual requirements govern. Reference the member's benefit documents and plan language when making coverage decisions.

In case of conflict, follow the applicable law or contract language.
Document the cited contractual requirement in the authorization request if relying on it.

Documentation Required

Documentation for biodegradable spacer placement

For transperineal placement of biodegradable spacers (e.g., hydrogel, balloon systems) used with radiotherapy, include device name, intended use with radiotherapy, imaging confirmation (CT/MRI/ultrasound), and consent documenting discussion of risks and expected benefits. Spacer placement for radiotherapy is supported; other indications are unproven and generally not medically necessary.

Include pre‑procedure imaging for treatment planning and post‑placement imaging to document spacer position when available.
If requesting spacer for non‑radiotherapy indications, provide supporting evidence and rationale.

Documentation Required

Expected clinical documentation (age, IPSS, prostate volume)

Expected clinical documentation for most BPH procedural authorizations should include: patient age, baseline IPSS with subscores, prostate volume (TRUS or imaging), Qmax and PVR, prior medical therapy (agents and duration), prior procedures, and symptom impact on quality of life.

Report objective measures at baseline (IPSS, Qmax, PVR) and prior interventions/medications and response.
Specify prostate anatomy including median lobe status and measured volume.

Documentation Required

Required clinical documentation (indication, imaging, consent)

Required clinical documentation for procedural authorization must include the indication for the procedure, relevant imaging (TRUS, CT, MRI) or uroflow studies, informed consent, and documentation of prior conservative/medical management. For procedures with specific criteria (e.g., PUL, Rezūm, Aquablation), include prostate size and anatomic eligibility.

Indication and symptom severity (IPSS) documented in chart notes.
Imaging and objective urodynamics or uroflow results when indicated.
Informed consent and procedure‑specific eligibility (e.g., prostate size limits).

Documentation Required

Required clinical documentation for PAE in high‑risk patients

For PAE requests in high‑risk surgical patients, include ASA score or comorbidity summary, rationale why TURP/standard surgical options are unsuitable, prior catheter dependence if present, and objective measures (IPSS, prostate volume, Qmax). High‑risk patient documentation improves consideration for PAE when standard surgery is contraindicated.

Document comorbidities that confer high anesthesia/surgical risk (ASA classification, cardiac/pulmonary/renal comorbidities).
If PAE is requested due to catheter dependency, include details of catheterization and attempts at conservative management.

Note

Documentation and decision guidance — reference contracts/plan terms when in conflict

When clinical evidence is limited or contested, include supporting literature, patient‑level data, and a clear plan for follow‑up and retreatment if needed. Reference InterQual or guideline criteria used to justify the request and cite plan/contract terms when invoking coverage exceptions.

Attach relevant trial publications or guideline recommendations that match the patient's clinical profile.
If seeking exception to standard coverage, reference the specific contractual language or state requirement supporting the request.

Step Therapy

Step therapy expectation (Aquablation studies often discontinued meds post‑procedure)

Step therapy expectations: document prior trials of conservative measures and medications (alpha‑blockers, 5‑alpha reductase inhibitors) and duration. Note that some procedural trials (e.g., Aquablation) report discontinuation of medical therapy post‑procedure; include medication history to demonstrate failure of or intolerance to medical therapy.

Specify medication names, dosages, duration, and clinical response.
If step therapy is being bypassed, provide justification (intolerance, contraindication, or urgent clinical need).

Step Therapy

Step therapy considerations for PAE

Step therapy considerations for PAE: document prior medical management and why step therapy options are not appropriate or have failed. For patients seeking PAE, include explicit documentation of medical therapy trials and reason for proceeding to PAE (e.g., refractory symptoms, intolerance, high surgical risk).

Provide dates and outcomes of medical therapy trials.
If claiming intolerance to medical therapy, include adverse event documentation.

Step Therapy

Medical therapy trial before PAE

A trial of medical therapy is generally expected before electing PAE for BPH‑related LUTS unless there are clear contraindications. Document the medical therapy attempted (alpha‑blocker, 5‑ARI) and duration and note failure, intolerance, or contraindication.

If medical therapy was not attempted, provide clinical justification (e.g., severe intolerance, immediate need for intervention).
For PAE considered in place of TURP due to surgical risk, include objective surgical risk assessments.

Documentation Required

Consider guideline-preferred alternatives

Consider guideline‑preferred alternatives when appropriate (TURP, HoLEP, PUL for eligible patients, water vapor therapy, or open/robotic prostatectomy for very large glands). Document why alternatives are unsuitable for the patient when requesting less‑established procedures.

If selecting a less‑established procedure, provide comparative rationale and evidence for patient‑specific benefit.
Reference guideline statements supporting preferred alternatives and how the patient differs from trial populations.

Step Therapy

Step therapy — no explicit requirements specified in these chunks

Step therapy: this policy does not specify uniform mandatory step therapy sequences for all plans. Follow the member's plan documents for any step therapy requirements. When applicable, document prior steps taken and provide justification for exception requests.

Check the member's benefit plan for step therapy rules.
When requesting bypass of step therapy, include clinical justification and supporting documentation.

30–80 cc (Roehrborn PUL trial; many device trials)

Larger gland inclusion in aquablation series80–150 cc (WATER II prospective series mean PV 107 cc)

Overall reported study rangeVaries across studies from ~20–150 cc depending on procedure and trial

Prostate volume exclusion in pivotal SpaceOAR trial

SpaceOAR pivotal trial exclusionPatients with prostate volume > 80 mL were excluded from the randomized pivotal trial

Trial population222 patients randomized in pivotal SpaceOAR trial with CT/MRI planning and fiducial placement

Implication for useProceed cautiously when prostate volume >80 mL as trial evidence excluded these patients

iTind (temporary implantable nitinol device) prostate volume inclusion

iTind prostate volume inclusion (RCT)Prostate volume between 25 and 75 cc (inclusion criteria in RCTs)

Associated flow/IPSS criteriaIPSS ≥10 and Qmax ≤12 mL/sec commonly required in trials

Age criteria in studiesParticipants generally aged ≥50 in pivotal iTind trials

PAE trial age and symptom thresholds

PAE trial age inclusionTrials enrolled men aged ≥40 or ≥45 years (varies by study)

Symptom/refractory criteriaParticipants commonly had refractory LUTS despite medical management (eg, failed alpha-blocker therapy)

IPSS thresholds in some PAE trialsSome trials included patients with high baseline IPSS (eg, mean/thresholds reflecting moderate-to-severe LUTS)

IPSS inclusion thresholds (trial examples)

iTind IPSS inclusioniTind RCT required IPSS ≥ 10

Optilume (PINNACLE) IPSS inclusionOptilume PINNACLE trial required IPSS ≥ 13

Use in documentationBaseline IPSS commonly required for eligibility and authorization documentation

Peak urinary flow rate (Qmax) inclusion thresholds

iTind Qmax inclusioniTind trials included peak urinary flow rate (Qmax) ≤ 12 mL/sec

Optilume Qmax inclusionOptilume PINNACLE trial required Qmax between 5 and 12 mL/sec

Measurement conditionsQmax assessed with appropriate voided volume requirements (eg, 125 mL in iTind trial)

Prostate volume — study inclusion ranges (summary)

iTind prostate volume window25–75 cc (RCT inclusion)

Optilume prostate volume window20–80 g (PINNACLE trial inclusion)

Guideline/device windowsCommon guideline/device windows often cited around 30–80 g for minimally invasive BPH devices

Post-void residual (PVR) exclusion threshold

Optilume PVR exclusion thresholdPost-void residual (PVR) > 300 mL was an exclusion in the PINNACLE trial

PVR measurement in follow-upPVR assessed at baseline and during follow-up to monitor urinary retention risk

Implication for eligibilityHigh PVR (eg, >300 mL) may preclude trial-based device eligibility and warrant additional evaluation

DefinitionTransurethral water jet ablation (Aquabeam) is a heat-free, image-guided, robotic-assisted water jet system for ablation and resection/removal of benign prostate tissue to treat LUTS due to BPH.

Regulatory noteAquabeam Robotic System received 510(k) clearance (March 3, 2021) as a Class II device for resection/removal of prostate tissue

Clinical intentAimed at symptom relief with potential preservation of sexual function compared with TURP in trial data

Definition — Prostatic urethral lift (PUL / UroLift)

DefinitionProstatic urethral lift (PUL; UroLift) places permanent implants to hold open lateral and median lobes of the prostate and reduce urinary obstruction from BPH.

Clinical outcomesTrials report durable symptom improvement, rapid recovery, and preservation of sexual function compared with some alternatives

Typical trial criteriaIncluded patients with IPSS>12, Qmax ≤12 mL/s, and prostate volumes often 30–80 cc in pivotal trials

Definition — Transperineal biodegradable spacer (hydrogel/balloon)

DefinitionTransperineal biodegradable spacer: injectable or implantable material placed between the prostate and rectum (eg, hydrogel, hyaluronic gel, balloon spacer) to protect the rectum during radiotherapy and reduce rectal dose/toxicity.

ExamplesSpaceOAR (PEG hydrogel), Barrigel (hyaluronic gel), and BioProtect balloon spacer

Visualization and planningSpacers are placed under transrectal ultrasound guidance and are visible on CT, MRI, and ultrasound for radiotherapy planning

Definition — ASTRO Phoenix biochemical recurrence definition

ASTRO Phoenix definition useThe ASTRO Phoenix definition is used in prostate cancer studies to define biochemical recurrence; multiple cryoablation studies reported recurrence using this definition.

ContextReferenced in systematic reviews and included studies assessing oncologic outcomes after cryoablation

Typical timeframeStudies reported recurrence intervals using Phoenix definition ranges noted in primary and salvage series

Definition — International Prostate Symptom Score (IPSS)

DefinitionIPSS (International Prostate Symptom Score) is a validated questionnaire measuring lower urinary tract symptom severity and quality of life impact in BPH trials and clinical practice.

Use in trialsUsed as primary or key secondary outcome in PUL, aquablation, iTind, Optilume, and other device trials

Typical thresholdsTrial inclusion thresholds commonly referenced: IPSS ≥10 or ≥13 depending on study

Definition — Hydrogel rectal spacer (SpaceOAR)

DefinitionHydrogel rectal spacer (SpaceOAR) is a polyethylene glycol–based absorbable hydrogel injected transperineally to create separation between prostate and rectum during radiotherapy, reducing rectal dose and toxicity.

Pivotal trial findingsRandomized pivotal trial (Mariados et al.) reported 99% hydrogel placement success and reduced rectal dose/toxicity and improved bowel QOL

Trial exclusionsPivotal trials excluded prostate volumes >80 mL and prior pelvic radiation/surgery in some studies

Definition — Aquablation (Transurethral Waterjet Ablation)

DefinitionAquablation (Transurethral Waterjet Ablation) is an image-guided, robotic-assisted transurethral waterjet tissue ablation technology for treating BPH-related LUTS.

Clinical evidence noteRCT evidence (WATER trial) compares aquablation to TURP with demonstrated noninferiority for symptom relief and potential ejaculatory preservation

Typical prostate size in trialsRCTs often limited to prostate size ≤80 cc, though series include larger glands up to 150 cc

Definition — Prostate Artery Embolization (PAE)

DefinitionProstate artery embolization (PAE) is endovascular occlusion of prostatic arterial supply using microspheres to reduce prostate volume and relieve LUTS.

Clinical contextEvaluated for patients unsuitable for surgery or refractory to medical therapy; trials show short-term symptom benefits but inferior long-term functional outcomes versus TURP in RCTs

Regulatory/devicesEmbosphere microspheres received De Novo for PAE; device options vary by vendor

Definition — Transperineal Focal Laser Ablation (FLA/TPLA)

DefinitionTransperineal Focal Laser Ablation (FLA/TPLA) is minimally invasive focal thermal ablation of MRI-visible prostate tumor or focal prostate tissue using laser energy delivered transperineally under imaging guidance.

Evidence noteEvidence is limited and insufficient to support routine oncologic use; proposed for focal treatment or symptom relief in selected settings or trials

Safety/effectivenessLong-term oncologic outcomes and comparative effectiveness remain uncertain

Definition — Prostate Artery Embolization (PAE) (alternate summary)

DefinitionPAE: endovascular occlusion of prostatic arterial supply using microspheres to reduce prostate volume and relieve LUTS; assessed in RCTs and case series.

Patient selectionOften considered for patients at high surgical risk or refractory to medical therapy; comparative trials vs TURP show mixed results

Outcomes cautionPAE associated with higher retreatment rates in some trials (eg, 21% required TURP within 2 years) and shorter-term safety benefit vs TURP

Definition — Temporary implantable nitinol device (iTind)

DefinitionTemporary implantable nitinol device (iTind) is a temporary urethral stent-like implant placed to relieve prostatic obstruction for months and later removed; intended as a short-term, minimally invasive BPH treatment.

Trial inclusionRCTs included IPSS ≥10, Qmax ≤12 mL/sec, prostate volume 25–75 cc

Regulatory noteDe Novo granted in December 2017 with subsequent 510(k) clearance (per FDA statements in document)

Definition — iTind / temporary implanted prostatic device (TIPD)

DefinitioniTind / TIPD: temporarily implanted nitinol device placed in the prostatic urethra to remodel tissue and relieve obstruction; studied in RCTs and case series with follow-up up to 36 months.

Outcomes notedStudies show IPSS improvements and variable durability; evidence quality limited by mixed results and loss to follow up

Use considerationMay be considered in select patients matching trial criteria or within research settings

Definition — Transurethral drug‑coated balloon (Optilume)

DefinitionTransurethral drug-coated balloon (Optilume) is a catheter-based balloon delivering an antiproliferative drug (eg, paclitaxel) to the prostatic urethra during dilation to maintain luminal patency and reduce LUTS.

PINNACLE trial criteriaPINNACLE required men 50–80 years, IPSS ≥13, Qmax 5–12 mL/s, prostate volume 20–80 g, and excluded PVR >300 mL

Regulatory noteOptilume Urethral Drug Coated Balloon received FDA PMA clearance (June 30, 2023)

Definition — Magnetic nanoparticle thermal ablation

DefinitionMagnetic nanoparticle thermal ablation involves intraprostatic injection of magnetic nanoparticles followed by an alternating magnetic field to induce thermal ablation of malignant prostate tissue.

Evidence concernsPhase I trials report inconsistent nanoparticle distribution, technical challenges, and significant adverse events including grade 3 urinary toxicities and QoL declines

Current stanceInsufficient evidence for routine use outside clinical trials; further research required

Definition — Spanner (temporary prostatic stent)

DefinitionSpanner: Temporary prostatic stent approved by FDA under PMA on December 14, 2006, intended to maintain urine flow temporarily in men with BPH-related obstruction.

Regulatory contextSpanner is an FDA-approved temporary prostatic stent (PMA) with specific indications and labeling

Use considerationsTemporary stents have limited evidence; selection and counseling important due to mixed results in trials

iTind / ITind system regulatory note

Regulatory noteiTind system received FDA De Novo (DEN190020) in December 2017 and subsequent 510(k) clearance (K210138)

ImplicationDevice regulatory status informs availability but does not alone determine coverage; trial evidence remains limited

DocumentationRegulatory references provided in policy for device context and manufacturer claims

Aquabeam Robotic System regulatory note

Regulatory noteAquabeam Robotic System received 510(k) clearance (K202961) on March 3, 2021 as a Class II device for resection/removal of prostate tissue in males with LUTS due to BPH.

Clinical relevance510(k) clearance supports device use but clinical coverage depends on evidence and guideline alignment

Device descriptionImage-guided, robotic-assisted waterjet tissue ablation technology

Optilume Urethral Drug Coated Balloon regulatory note

Regulatory noteOptilume Urethral Drug Coated Balloon received FDA PMA clearance (June 30, 2023) for treatment of obstructive urinary symptoms associated with BPH in men ≥50 years.

Trial contextPINNACLE randomized sham-controlled trial supported efficacy through 1 year; longer-term comparative data lacking

Coverage implicationPMA clearance does not by itself determine payer coverage; evidence and guidelines considered for medical necessity